Saturday, 31 October 2026European Markets

BOUVET And LINEDATA SERVICES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - bouvet (bouv.ol) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
bouvet (bouv.ol) kr63.20 4.08% 60.9%
linedata services (lin.pa) €68.40 2.46% 24.06%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bouvet (bouv.ol)

4.08% forward dividend yield and 60.9% return on equity

bouvet asa provides it and digital communication consultancy services for public and private sector companies in norway, sweden, and internationally. the company was incorporated in 1995 and is headquartered in oslo, norway.

earnings per share

as for profitability, bouvet has a trailing twelve months eps of kr3.14.

pe ratio

bouvet has a trailing twelve months price to earnings ratio of 20.13. meaning, the purchaser of the share is investing kr20.13 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.9%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 24, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 4.08%.

more news about bouvet.

2. linedata services (lin.pa)

2.46% forward dividend yield and 24.06% return on equity

linedata services s.a. develops, publishes, and distributes financial software in southern europe, northern europe, north america, and asia. it operates through asset management and lending & leasing segments. the company provides solutions for asset managers and servicers, such as order management trading, investment compliance, risk management, and oversights; software for fund accounting, fund oversight, and transfer agency; analytics and data services; reconciliation solution and expense management; and investment data analytics and cognitive investment data management. it also offers solutions for lenders and lessors, such as commercial and syndicated lending, as well as for automotive, consumer, and equipment finance; and digitalization, marketplace, outsourced spreading, professional and hosting, and remarketing services, as well as business process as a service. in addition, the company provides advisory, risk and research, middle and office, and risk services, as well as technology solutions. linedata services s.a. was incorporated in 1998 and is headquartered in neuilly-sur-seine, france.

earnings per share

as for profitability, linedata services has a trailing twelve months eps of €4.03.

pe ratio

linedata services has a trailing twelve months price to earnings ratio of 16.97. meaning, the purchaser of the share is investing €16.97 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.06%.

more news about linedata services.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
BOUVET And LINEDATA SERVICES Have A High Dividend Yield And Return On Equity In The Technology Sector. | ViaNews EU